PD-1/PD-L1抑制剂治疗转移性结直肠癌的研究进展  

Research progress of PD-1/PD-L1 inhibitors in the treatment of metastatic colorectal cancer

作　　者：尹竺晟 梁新军[1] YINZhucheng;LIANG Xinjun(Departments of Abdominal Oncology,Hubei Clinical Medical Research Center for Colorectal Cancer,Wuhan Colorectal Cancer Clinical Medical Research Center,Hubei Cancer Hospital,Hubei Province,Wuhan 430070,China)

机构地区：[1]湖北省肿瘤医院腹部肿瘤内科,湖北省结直肠癌临床医学研究中心,武汉市结直肠癌临床医学研究中心,湖北武汉430070

出　　处：《中国医药导报》2022年第26期39-42,57,共5页China Medical Herald

基　　金：湖北省技术创新专项(重大项目)(2019ACA135);湖北省武汉市科技计划项目(2020020601012250)。

摘　　要：结直肠癌是全球最常见的恶性肿瘤之一,大部分患者诊断时已发生转移,其预后较差。近年来免疫检查点抑制剂在多种恶性肿瘤治疗方面取得了突破性进展,是目前的研究热点之一。程序性死亡受体1(PD-1)/程序性死亡受体配体1(PD-L1)抑制剂单药或联合治疗可给DNA错配修复缺陷/高微卫星不稳定性转移性结直肠癌(mCRC)患者带来临床获益。错配修复完整/微卫星稳定mCRC患者单药免疫治疗效果差,目前正在探索PD-1/PD-L1抑制剂联合治疗的可行性。本文对PD-1/PD-L1抑制剂在mCRC患者一线、二线和后线治疗中的应用,以及不同类型mCRC患者的PD-1/PD-L1抑制剂单药及联合治疗的临床研究现状及进展进行综述,为临床应用提供依据。Colorectal cancer is one of the most common malignant tumors in the world.Most patients have metastases at diagnosis,the prognosis is poor.In recent years,immune checkpoint inhibitors have made a breakthrough progress in the treatment of a variety of malignant tumors,which is one of the current research hotspots.Monotherapy or combination therapy with programmed death-1(PD-1)/programmed cell death ligand-1(PD-L1)inhibitors may provide clinical benefit for patients with DNA mismatch repair defects/high microsatellite instability metastatic colorectal cancer(mCRC).The efficacy of monotherapy in patients with mismatch repair proficient/microsatellite stable mCRC is poor,and the feasibility of combination therapy with PD-1/PD-L1 inhibitors is being explored.This article reviews the application of PD-1/PD-L1 inhibitors in first-line,second-line,and posterior line treatment of mCRC patients,as well as the clinical research status and progress of PD-1/PD-L1 inhibitors monotherapy and combination therapy in different types of mCRC patients,so as to provide evidence for clinical application.

关 键 词：转移性结直肠癌 PD-1/PD-L1抑制剂 DNA错配修复缺陷/高微卫星不稳定性 错配修复完整/微卫星稳定 免疫联合治疗 

分 类 号：R735.3[医药卫生—肿瘤]